Innovent Biologics, Inc. has achieved a landmark moment in China’s clinical research trajectory with the back-to-back publication of two Phase 3 clinical trials of mazdutide, a dual GCG/GLP-1 receptor agonist, in Nature as Accelerated Article Previews. These studies, known as DREAMS-1 and DREAMS-2, evaluated the drug as monotherapy and as an add-on therapy in Chinese adults with type 2 diabetes. The publications arrive on the heels of National Medical Products Administration approvals granted earlier in 2025 for glycemic control and long-term weight management. The news positions mazdutide as not only a first-in-class molecule but also as a symbol of China’s fast-evolving ambitions in global drug innovation.

What this dual-receptor publication reveals about China’s global ambitions in metabolic innovation

The simultaneous publication of two pivotal Phase 3 trials in Nature is unprecedented for a metabolic drug developed entirely in China. This milestone positions Innovent Biologics, Inc. among the rare few to gain validation in both Nature and The New England Journal of Medicine, with the earlier GLORY-1 obesity trial published in May 2025. For China’s biotech ecosystem, this sets a new benchmark in academic recognition and signals readiness to compete on the international stage not just in oncology or rare diseases but in mainstream chronic disease management.

Mazdutide’s mechanism of action offers a distinctive clinical profile. By combining glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) agonism, it delivers simultaneous improvements in glycemic control, body weight, and hepatic fat metabolism. This design enables broader metabolic coverage than traditional GLP-1 receptor agonists, which primarily suppress appetite and delay gastric emptying. The DREAMS program has demonstrated that dual activation also enhances energy expenditure and fat oxidation, factors particularly relevant to Asian populations that tend to present with central obesity and insulin resistance even at lower body mass index thresholds.

Why the DREAMS trials set a new bar for real-world GLP-1 innovation in China

The DREAMS-1 study enrolled 320 treatment-naïve Chinese adults with type 2 diabetes and demonstrated a 2.02 percent HbA1c reduction at Week 24 in the 6 mg mazdutide group. The weight loss effects were equally notable, with a 7.34 percent reduction observed. This dual benefit in a monotherapy setting is significant. The 81.8 percent of participants achieving HbA1c below 7 percent with mazdutide 6 mg outperforms many existing GLP-1 comparators in monotherapy trials, underlining the potency of the GCG component.

In the DREAMS-2 study, which included 731 participants with insufficient glycemic control on oral anti-diabetic drugs, mazdutide again outperformed dulaglutide 1.5 mg. At Week 28, the 6 mg dose of mazdutide achieved a 1.66 percent reduction in HbA1c compared to 1.36 percent with dulaglutide. Notably, 59.9 percent of participants achieved both glycemic control and at least 5 percent weight loss on the higher dose of mazdutide, versus 18.9 percent in the dulaglutide arm. These findings are consistent with a growing body of Phase 3 evidence supporting the drug’s dual-receptor efficacy.

The trials also demonstrated broader metabolic improvements across fasting plasma glucose, waist circumference, lipid profiles, liver enzymes, and blood pressure, suggesting a wider impact on cardiometabolic health. This could potentially position mazdutide as a cornerstone agent for a spectrum of metabolic diseases beyond diabetes, including nonalcoholic fatty liver disease, obesity-related hypertension, and even early-stage heart failure.

What this reveals about the competitive future of dual-receptor agonists in diabetes

Mazdutide is currently the only GCG/GLP-1 dual receptor agonist approved for commercial use, with National Medical Products Administration endorsements in both weight management and type 2 diabetes. While other dual agonists such as cotadutide and LY3437943 remain in clinical development in the West, mazdutide’s front-runner status makes it a test case for real-world deployment of dual-receptor therapies.

The clinical development program behind mazdutide is broad. In addition to DREAMS-1 and DREAMS-2, Innovent Biologics, Inc. has reported positive results from DREAMS-3, a head-to-head Phase 3 trial versus semaglutide. That study demonstrated superiority in achieving the combined goal of glycemic control and at least 10 percent weight loss, with nearly half of patients on mazdutide reaching this threshold versus only 21 percent on semaglutide. Future trials including GLORY-2 in obesity and GLORY-3 in metabolic-associated fatty liver disease further extend the drug’s potential reach across the metabolic disease spectrum.

Why China’s regulatory and population context gives Innovent an edge

China is home to the world’s largest diabetes population, with over 148 million people estimated to have the disease in 2024. This figure is projected to exceed 168 million by 2050. Unlike Western populations, where type 2 diabetes is typically associated with high BMI, Chinese patients frequently exhibit insulin resistance and central adiposity at relatively lower body mass indexes. Mazdutide’s pharmacodynamic profile addresses this through enhanced intrahepatic lipolysis and glucagon-driven energy expenditure.

The regulatory context is equally significant. The speed with which Innovent Biologics, Inc. secured National Medical Products Administration approvals in two separate indications within a span of months reflects both the robustness of its clinical data and the Chinese government’s prioritization of local innovation. Mazdutide was rapidly incorporated into China’s clinical consensus guidelines for obesity and diabetes, suggesting that widespread adoption and reimbursement discussions are already underway.

What could still limit mazdutide’s global uptake despite clinical strength

Despite its strong domestic momentum, mazdutide’s global pathway remains uncertain. The licensing agreement between Innovent Biologics, Inc. and Eli Lilly and Company restricts Innovent’s rights to China, meaning that any international expansion will either require additional licensing deals or coordinated multinational studies.

There are also outstanding questions around long-term cardiovascular safety. While the drug has demonstrated improvements in cardiometabolic parameters such as blood pressure and lipid profiles, it does not yet carry a cardiovascular outcomes label. In contrast, agents like semaglutide and tirzepatide already hold cardiovascular risk reduction indications in the United States and Europe. Any attempt to expand mazdutide’s global market footprint will likely require a dedicated cardiovascular outcomes trial.

Furthermore, while the safety profile of mazdutide was consistent with other GLP-1 agents—primarily transient gastrointestinal effects during dose escalation—it will need to demonstrate tolerability in broader populations, particularly in those outside of China. The absence of severe hypoglycemia is promising, but global regulators and clinicians will want more post-marketing data.

What the strategic roadmap looks like for mazdutide heading into 2026

Mazdutide is now at a pivotal juncture. It has secured local regulatory approvals, entered national guidelines, and garnered international academic recognition. If Innovent Biologics, Inc. can continue its momentum across the GLORY and DREAMS Phase 3 programs, the drug may emerge as the first homegrown Chinese therapeutic platform with cross-border relevance in chronic disease management.

Strategically, the next steps will involve expanding access across Chinese provinces, deepening real-world evidence collection, and potentially initiating discussions for global co-development with Eli Lilly and Company or other multinational partners. The company has also announced future clinical plans in adolescents, obstructive sleep apnea, and heart failure with preserved ejection fraction—further demonstrating that it views mazdutide not as a single-product success, but as a platform therapy.

With the GLP-1 class rapidly evolving to include tri-agonists and multi-pathway designs, Innovent’s ability to scale, differentiate, and navigate international regulatory systems will determine whether mazdutide becomes a domestic champion or a global category leader.

  China biotech, dulaglutide, endocrinology, GCG GLP-1 dual receptor agonist, GLP-1 therapies, Innovent Biologics, mazdutide, metabolic disease, obesity treatment, semaglutide comparison, type 2 diabetes